Not investment advice. Educational platform. See Disclaimer.
NASDAQ: PHAT
Phathom Pharmaceuticals, Inc.
Healthcare | Biotechnology
No licensed closing price on file for PHAT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
EPS (TTM)$-2.09
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:47 UTC.
Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
2025-10-06Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-04-16Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-04-01Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
Phathom Pharmaceuticals, Inc. is a biotechnology company, listed on NASDAQ as PHAT.
When did PHAT last file with the SEC?
Phathom Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-23. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:47 UTC. This page is also available as JSON at /api/data?ticker=PHAT and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for PHAT and 5,000+ tickers.
Oxford Ledge
Search